ConductScience.org, home

Paper19463580

Adjuvant radiotherapy after modified Ivor-Lewis esophagectomy: can it prevent lymph node recurrence of the mid-thoracic esophageal carcinoma?

Chen G and 3 others. Ann Thorac Surg, 2009. Cited by 27 papers, by iCite.

Cite this record

ConductScience Library. Adjuvant radiotherapy after modified Ivor-Lewis esophagectomy: can it prevent lymph node recurrence of the mid-thoracic esophageal carcinoma? Papers, record 19463580. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19463580

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Adjuvant radiotherapy after modified Ivor-Lewis esophagectomy: can it prevent lymph node recurrence of the mid-thoracic esophageal carcinoma?
PubMed
Journal
Ann Thorac Surg
PubMed
Year
2009
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
27
iCite
Relative citation ratio, by iCite
0.77
iCite
Revised in PubMed
2022-03-18
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chen GGang
2Wang ZZhou
3Liu XYXiang-Yan
4Liu FYFan-Ying

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Squamous CellMajor topic
Esophageal NeoplasmsMajor topic
EsophagectomyMajor topic
Neoplasm Recurrence, LocalMajor topic
Adult
Aged
Aged, 80 and over
Female
Humans
Lymphatic Metastasis
Male
Middle Aged
Radiotherapy, Adjuvant
Retrospective Studies

Source PubMed

Download CSV of topics

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in19463581Invited commentary.https://conductscience.org/library/papers/19463581

Source PubMed

Download CSV of comments and corrections

Cited by15

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.

PMIDTitleJournalYearIn PapersSource
38627783A approach of gastric conduit via the anterior of pulmonary hilum route during minimally invasive McKeown esophagectomy.J Cardiothorac Surg2024https://conductscience.org/library/papers/38627783PubMed
31943824Radical esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma followed by adjuvant radiotherapy with or without chemotherapy: Which is more beneficial?Thorac Cancer2020https://conductscience.org/library/papers/31943824PubMed
30461614Comparison of the effect of postoperative radiotherapy with surgery alone for esophagus squamous cell carcinoma patients: A meta-analysis.Medicine (Baltimore)2018https://conductscience.org/library/papers/30461614PubMed
30050313CEP55 promotes the proliferation, migration and invasion of esophageal squamous cell carcinoma via the PI3K/Akt pathway.Onco Targets Ther2018https://conductscience.org/library/papers/30050313PubMed
28857475Overexpression of IFITM3 predicts poor prognosis in stage IIA esophageal squamous cell carcinoma after Ivor Lewis esophagectomy.Thorac Cancer2017https://conductscience.org/library/papers/28857475PubMed
28243329Adjuvant Therapy for a Microscopically Incomplete Resection Margin after an Esophagectomy for Esophageal Squamous Cell Carcinoma.J Cancer2017https://conductscience.org/library/papers/28243329PubMed
27338033Optimal Adjuvant Treatment for Curatively Resected Thoracic Esophageal Squamous Cell Carcinoma: A Radiotherapy Perspective.Cancer Res Treat2017https://conductscience.org/library/papers/27338033PubMed
26539332Overexpression of IFITM3 predicts the high risk of lymphatic metastatic recurrence in pN0 esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy.PeerJ2015https://conductscience.org/library/papers/26539332PubMed
26328915The impact of adjuvant radiotherapy on radically resected T3 esophageal squamous cell carcinoma.J Cancer Res Clin Oncol2016https://conductscience.org/library/papers/26328915PubMed
25758053Prognostic significance of Ku80 in pT2N0M0 esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy.Tumour Biol2015https://conductscience.org/library/papers/25758053PubMed
25711486Overexpression of Ku80 suggests poor prognosis of locally advanced esophageal squamous cell carcinoma patients.World J Surg2015https://conductscience.org/library/papers/25711486PubMed
22811814Radiation therapy in the postoperative management of esophageal cancer.J Gastrointest Oncol2010https://conductscience.org/library/papers/22811814PubMed
22700258A meta-analysis of lymph node metastasis rate for patients with thoracic oesophageal cancer and its implication in delineation of clinical target volume for radiation therapy.Br J Radiol2012https://conductscience.org/library/papers/22700258PubMed
22591456Gastric tube resection due to metachronic cancer and a recurrence in anastomosis after Ivor-Lewis esophagectomy--case report.World J Surg Oncol2012https://conductscience.org/library/papers/22591456PubMed
19842230Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma.World J Gastroenterol2009https://conductscience.org/library/papers/19842230PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19463580

GET https://conductscience.org/api/papers/v1/19463580/authors